Davide V Moretti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7473439/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Individual analysis of EEG frequency and band power in mild Alzheimer's disease. Clinical Neurophysiology, 2004, 115, 299-308.	1.5	311
2	Sources of cortical rhythms change as a function of cognitive impairment in pathological aging: a multicenter study. Clinical Neurophysiology, 2006, 117, 252-268.	1.5	260
3	Mapping distributed sources of cortical rhythms in mild Alzheimer's disease. A multicentric EEG study. NeuroImage, 2004, 22, 57-67.	4.2	253
4	Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's and Dementia, 2018, 14, 280-292.	0.8	246
5	Computerized processing of EEG–EOG–EMG artifacts for multi-centric studies in EEG oscillations and event-related potentials. International Journal of Psychophysiology, 2003, 47, 199-216.	1.0	238
6	Human Cortical Electroencephalography (EEG) Rhythms during the Observation of Simple Aimless Movements: A High-Resolution EEG Study. NeuroImage, 2002, 17, 559-572.	4.2	198
7	What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons. Neurobiology of Aging, 2020, 85, 58-73.	3.1	150
8	The Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's and Dementia, 2017, 13, 624-633.	0.8	143
9	Abnormal frontoâ€parietal coupling of brain rhythms in mild Alzheimer's disease: a multicentric EEG study. European Journal of Neuroscience, 2004, 19, 2583-2590.	2.6	137
10	Progranulin Leu271LeufsX10 is one of the most common FTLD and CBS associated mutations worldwide. Neurobiology of Disease, 2009, 33, 379-385.	4.4	107
11	MCI patients' EEGs show group differences between those who progress and those who do not progress to AD. Neurobiology of Aging, 2011, 32, 563-571.	3.1	98
12	Donepezil effects on sources of cortical rhythms in mild Alzheimer's disease: Responders vs. Non-Responders. Neurolmage, 2006, 31, 1650-1665.	4.2	97
13	Increase of theta/gamma ratio is associated with memory impairment. Clinical Neurophysiology, 2009, 120, 295-303.	1.5	87
14	Hippocampal atrophy and EEG markers in subjects with mild cognitive impairment. Clinical Neurophysiology, 2007, 118, 2716-2729.	1.5	78
15	Human cortical electroencephalography (EEG) rhythms during the observation of simple aimless movements: a high-resolution EEG study. NeuroImage, 2002, 17, 559-72.	4.2	74
16	Human cortical EEG rhythms during long-term episodic memory task. A high-resolution EEG study of the HERA model. NeuroImage, 2004, 21, 1576-1584.	4.2	66
17	Vascular damage and EEG markers in subjects with mild cognitive impairment. Clinical Neurophysiology, 2007, 118, 1866-1876.	1.5	66
18	Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel. Alzheimer's and Dementia, 2021, 17, 1528-1553.	0.8	64

DAVIDE V MORETTI

#	Article	IF	CITATIONS
19	Human cortical responses during one-bit short-term memory. A high-resolution EEG study on delayed choice reaction time tasks. Clinical Neurophysiology, 2004, 115, 161-170.	1.5	60
20	Cerebrovascular Disease and Hippocampal Atrophy Are Differently Linked to Functional Coupling of Brain Areas: An EEG Coherence Study in MCI Subjects. Journal of Alzheimer's Disease, 2008, 14, 285-299.	2.6	57
21	Increase of Theta/Gamma and Alpha3/Alpha2 Ratio is Associated with Amygdalo-Hippocampal Complex Atrophy. Journal of Alzheimer's Disease, 2009, 17, 349-357.	2.6	56
22	Human cortical rhythms during visual delayed choice reaction time tasks. Behavioural Brain Research, 2004, 153, 261-271.	2.2	52
23	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. Alzheimer's and Dementia, 2013, 9, 677-686.	0.8	51
24	EEG markers are associated to gray matter changes in thalamus and basal ganglia in subjects with mild cognitive impairment. NeuroImage, 2012, 60, 489-496.	4.2	48
25	Specific EEG Changes Associated with Atrophy of Hippocampus in Subjects with Mild Cognitive Impairment and Alzheimer's Disease. International Journal of Alzheimer's Disease, 2012, 2012, 1-8.	2.0	46
26	Theta and alpha EEG frequency interplay in subjects with mild cognitive impairment: evidence from EEG, MRI, and SPECT brain modifications. Frontiers in Aging Neuroscience, 2015, 7, 31.	3.4	46
27	Brain Vascular Damage of Cholinergic Pathways and EEG Markers in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2008, 15, 357-372.	2.6	44
28	Quantitative EEG Markers in Mild Cognitive Impairment: Degenerative versus Vascular Brain Impairment. International Journal of Alzheimer's Disease, 2012, 2012, 1-12.	2.0	44
29	EEG upper/low alpha frequency power ratio relates to temporo-parietal brain atrophy and memory performances in mild cognitive impairment. Frontiers in Aging Neuroscience, 2013, 5, 63.	3.4	44
30	Alpha rhythms in mild dements during visual delayed choice reaction time tasks: A MEG study. Brain Research Bulletin, 2005, 65, 457-470.	3.0	35
31	EEG Markers Discriminate Among Different Subgroup of Patients With Mild Cognitive Impairment. American Journal of Alzheimer's Disease and Other Dementias, 2010, 25, 58-73.	1.9	35
32	Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. Journal of Alzheimer's Disease, 2019, 69, 15-35.	2.6	34
33	Anatomical Substrate and Scalp EEG Markers are Correlated in Subjects with Cognitive Impairment and Alzheimer's Disease. Frontiers in Psychiatry, 2011, 1, 152.	2.6	33
34	Volumetric Differences in Mapped Hippocampal Regions Correlate with Increase of High Alpha Rhythm in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-7.	2.0	30
35	Chronic bilateral electrical stimulation of the subthalamic nucleus for the treatment of advanced Parkinson's disease. Neurological Sciences, 2001, 22, 57-58.	1.9	27
36	Increase of theta frequency is associated with reduction in regional cerebral blood flow only in subjects with mild cognitive impairment with higher upper alpha/low alpha EEG frequency power ratio. Frontiers in Behavioral Neuroscience, 2013, 7, 188.	2.0	24

DAVIDE V MORETTI

#	Article	IF	CITATIONS
37	Increasing Hippocampal Atrophy and Cerebrovascular Damage Is Differently Associated With Functional Cortical Coupling in MCI Patients. Alzheimer Disease and Associated Disorders, 2009, 23, 323-332.	1.3	23
38	Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 270-280.	6.4	23
39	Cortical Networks Generating Movement-Related EEG Rhythms in Alzheimer's Disease: An EEG Coherence Study Behavioral Neuroscience, 2004, 118, 698-706.	1.2	22
40	Conversion of mild cognitive impairment patients in Alzheimer's disease: prognostic value of Alpha3/Alpha2 electroencephalographic rhythms power ratio. Alzheimer's Research and Therapy, 2015, 7, 80.	6.2	22
41	Available and future treatments for atypical parkinsonism. A systematic review. CNS Neuroscience and Therapeutics, 2019, 25, 159-174.	3.9	22
42	Analysis of Grey Matter in Thalamus and Basal Ganglia Based on EEG α3/α2 Frequency Ratio Reveals Specific Changes in Subjects with Mild Cognitive Impairment. ASN Neuro, 2012, 4, AN20120058.	2.7	21
43	Synchronization of gamma oscillations increases functional connectivity of human hippocampus and inferior-middle temporal cortex during repetitive visuomotor events. European Journal of Neuroscience, 2004, 19, 3088-3098.	2.6	19
44	Predictors of comprehensive stimulation program efficacy in patients with cognitive impairment. Clinical practice recommendations. International Journal of Geriatric Psychiatry, 2013, 28, 26-33.	2.7	19
45	Electroencephalographic Upper/Low Alpha Frequency Power Ratio Relates to Cortex Thinning in Mild Cognitive Impairment. Neurodegenerative Diseases, 2014, 14, 18-30.	1.4	17
46	Transient human cortical responses during the observation of simple finger movements: A high-resolution EEG study. Human Brain Mapping, 2003, 20, 148-157.	3.6	16
47	Cerebral PET glucose hypometabolism in subjects with mild cognitive impairment and higher EEG high-alpha/low-alpha frequency power ratio. Neurobiology of Aging, 2017, 58, 213-224.	3.1	15
48	Anterior EEG slowing in dementia with Lewy bodies: a multicenter European cohort study. Neurobiology of Aging, 2020, 93, 55-60.	3.1	14
49	Association of EEG, MRI, and regional blood flow biomarkers is predictive of prodromal Alzheimer's disease. Neuropsychiatric Disease and Treatment, 2015, 11, 2779.	2.2	13
50	Electroencephalography-driven approach to prodromal Alzheimer's disease diagnosis: from biomarker integration to network-level comprehension. Clinical Interventions in Aging, 2016, Volume 11, 897-912.	2.9	13
51	Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both a-synucleinopathy and tauopathy. Neuropsychiatric Disease and Treatment, 2014, 10, 1003.	2.2	12
52	Behavioral and Neurophysiological Effects of Transdermal Rotigotine in Atypical Parkinsonism. Frontiers in Neurology, 2014, 5, 85.	2.4	12
53	Electroencephalography reveals lower regional blood perfusion and atrophy of the temporoparietal network associated with memory deficits and hippocampal volume reduction in mild cognitive impairment due to Alzheimer's disease. Neuropsychiatric Disease and Treatment, 2015, 11, 461	2.2	10
54	Mild Cognitive Impairment: Structural, Metabolical, and Neurophysiological Evidence of a Novel EEG Biomarker. Frontiers in Neurology, 2015, 6, 152.	2.4	10

DAVIDE V MORETTI

#	Article	IF	CITATIONS
55	Involvement of mirror neuron system in prodromal Alzheimer's disease. BBA Clinical, 2016, 5, 46-53.	4.1	9
56	Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimerââ,¬â,,¢s disease. Frontiers in Aging Neuroscience, 2014, 6, 179.	3.4	8
57	Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: A 24 months pilot observational open-label study. Neuropharmacology, 2014, 85, 284-289.	4.1	8
58	Progranulin Mutations Affects Brain Oscillatory Activity in Fronto-Temporal Dementia. Frontiers in Aging Neuroscience, 2016, 8, 35.	3.4	8
59	Understanding early dementia: EEG, MRI, SPECT and memory evaluation. Translational Neuroscience, 2015, 6, 32-46.	1.4	7
60	EEG Upper/Low Alpha Frequency Power Ratio and the Impulsive Disorders Network in Subjects with Mild Cognitive Impairment Current Alzheimer Research, 2014, 11, 192-199.	1.4	7
61	Shall I Move My Right or My Left Hand?. Journal of Psychophysiology, 2003, 17, 69-86.	0.7	6
62	Cortical network modularity changes along the course of frontotemporal and Alzheimer's dementing diseases. Neurobiology of Aging, 2022, 110, 37-46.	3.1	5
63	Increase of EEG Alpha3/Alpha2 Power Ratio Detects Inferior Parietal Lobule Atrophy in Mild Cognitive Impairment. Current Alzheimer Research, 2018, 15, 443-451.	1.4	4
64	Cortical alpha rhythms in mild Alzheimer's disease. A multicentric EEG study. International Congress Series, 2004, 1270, 44-49.	0.2	3
65	Chapter 55 High resolution EEG of sensorimotor brain functions: mapping ERPs or mu ERD?. Supplements To Clinical Neurophysiology, 2002, 54, 365-371.	2.1	2
66	Chapter 42 Quantitative EEG: modeling time, space, and phase of brain oscillatory activity. Supplements To Clinical Neurophysiology, 2002, , 284-288.	2.1	2
67	Are there treatments for atypical parkinsonism? An update on actual options. Reviews in the Neurosciences, 2015, 26, 547-553.	2.9	2
68	Editorial: Neurophysiology in Alzheimer's Disease and Dementia. Frontiers in Aging Neuroscience, 2016, 8, 153.	3.4	2
69	Alpha rhythm oscillations and MMSE scores are differently modified by transdermal or oral rivastigmine in patients with Alzheimer's disease. American Journal of Neurodegenerative Disease, 2014, 3, 72-83.	0.1	1
70	Possible Treatments of Atypical Parkinsonism. , 2016, , .		0
71	P.0741 Effect of a probiotic administration on inflammatory profile and clinical features in patients with Alzheimer's disease. European Neuropsychopharmacology, 2021, 53, S541.	0.7	0